SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a new 52-week high and bullish call-option activity are drawing attention ahead of the expected Q3 report, with traders watching BRIUMVIs sales momentum and guidance. Buyout speculation is adding to the excitement, but remains unconfirmed; some investors see the move as earnings positioning while others question whether expectations are already priced in.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Roots Hyundai Secure+ white-label insurance offering is drawing attention, with traders viewing the dealership channel as a potential source of policy growth while others question how quickly it will convert into business. The debate is set against concern about recent declines in policies in force and sluggish revenue growth, despite continued profitability.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXYs breakout to a six-month high and call-heavy options activity have drawn attention, alongside optimism that debt reduction and stronger free cash flow are improving the oil producers outlook. Traders are split between expecting further momentum and cautioning that the shares could stall after lagging crude at times.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1983 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Chenieres strong Q3 results, raised full-year guidance, dividend increase, and completion of its Corpus Christi expansion are driving attention as shares reach a new high. Many traders are bullish on the operating momentum, while some are taking profits or pointing to put-heavy options activity and the risk of a pause after the run-up.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is drawing attention after a third-quarter earnings beat, with growth in Dupixent and Eylea HD helping offset pressure on legacy Eylea. Traders largely welcomed the results and sharp share move, while some question whether newer products can sustain growth amid biosimilar competition.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys latest quarterly report has driven attention: despite revenue and earnings coming in below expectations, subscriber growth, stronger gross margins, and a better-than-expected next-quarter profit outlook have been credited for the stocks sharp rise. Traders are debating the disconnect between the headline miss and the upbeat guidance, with some questioning whether higher expenses and the recent run-up make the rally sustainable.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA filing for sonelokimab in hidradenitis suppurativa and the pending FDA acceptance and review-timeline decision are the main focus, with traders debating whether regulatory progress can revive the stock. Bulls point to the clinical data and commercial potential, while bears emphasize approval risk and the costs of launching alone; buyout talk remains speculative.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 data for Amgens cancer and Sjgrens disease programs are reinforcing bullish momentum as the shares approach highs. Traders are also focused on upcoming quarterly results, with some viewing put activity as earnings protection rather than a bearish bet.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders position for further Nasdaq weakness, citing tech and AI-spending concerns alongside market volatility. Some expect a deeper selloff, while others warn that reports of a possible U.S.-Iran deal and Strait of Hormuz reopening could fuel a rebound and hurt short positions.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The Trump-branded meme coin is drawing attention amid discussion of its steep decline and retail holders losses, with many traders calling it a cash grab. A smaller bullish contingent points to the recent bounce and speculates about an election-linked rebound or short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Monte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?

Investors need to pay close attention to GLUE stock based on the movements in the options market lately.

GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?

Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.read more...

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion.
Filana Therapeutics (NASDAQ:FLNA) shares roseread more...

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?

Equity

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.


After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Key PointsThe chief medical officer of Monte Rosa Therapeutics reported selling 41,845 shares directly for a transaction value of approximately $882,000, based on a weighted average price of around $21.08 per share over June 23-24, 2026...

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-monte-rosa-therapeutics-inc-stock...

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.</li><li>The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with related programs. &nbsp;</li><li>While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;</li></ul>Shares of BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) plunged on Friday after Novo Nordisk’s (NVO) late-stage trial setback raised concerns about biotech stocks pursuing similar approaches to treating heart disease through inflammation reduction. &nbsp;BIOA tumbled 64%, while GLUE dropped about 27%. BIOA clocked its worst day since December 2024, while GLUE booked its worst day ever.<h2 class="st-heading-2">NVO’s Trial Miss</h2>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS. The once-monthly treatment was designed to lower the risk of heart attacks, strokes, and related deaths in patients with heart and kidney problems plus high inflammation. While the drug successfully reduced inflammation markers as expected, it showed no benefit in cutting those major heart events compared with a placebo. The study involved more than 6,300 patients.Novo said the miss will not change its 2026 profit outlook and that two other trials of the same drug will continue. NVO shares closed 9% lower on Friday.The result also raised questions about whether targeting inflammation this way can meaningfully protect the heart, pressuring companies with related programs such as BioAge and Monte Rosa. While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;<h2 class="st-heading-2">Wall Street Weighs In</h2>Analysts weighed in on BioAge, whose lead candidate BGE-102 targets a similar approach as ziltivekimab. Jefferies cut its price target to $21 from $62 but kept a Buy rating, saying the “outright” failure raises biological risk for a key inflammation marker as a heart-risk signal. The firm still sees potential differentiation for BGE-102, but called its profile harder to predict now.Citi noted BIOA’s greater-than-60% drop and agreed the data is a negative for BioAge’s heart-disease thesis, yet argued the size of the move “seems overdone” with the company’s enterprise value nearing zero. Citi maintains a Buy rating and $52 price target.Roth Capital’s Adam Walsh lowered his price target to $25 from $36 while keeping a Buy rating. The firm now sees lower chances that a partner will fund a heart trial for BGE-102 or that it will succeed, but its estimates for the same drug in eye disease stay the same. &nbsp;The new price targets on BIOA represent a potential upside of 132% to 475% from the stock’s Friday close.Jefferies also cut its price target on Monte Rosa (GLUE) to $25 from $40, still implying a potential upside of 51% from the last close, and kept a Buy rating. Success in the ZEUS trial would have supported Monte Rosa’s approach to residual inflammation in heart disease with its experimental drug MRT-8102, so the miss is “a setback.” The firm still sees prospects in other indications and other pipeline value drivers. &nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BIOA improved from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high levels.’Meanwhile, sentiment around GLUE stock rose from ‘neutral’ to ‘bullish,’ accompanied by a rise in retail chatter.A Stocktwits user termed the selloff on Friday as an “oversold play” and voiced hopes for a recovery in the next few days.<stembedurl>https://www.stocktwits.com/Gemini367/message/660591844</stembedurl>While <a href="https://stocktwits.com/symbol/BIOA">BIOA stock</a> has fallen 32% year-to-date, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> has gained 5%.&nbsp;Read more: <a href="https://stocktwits.com/news-articles/markets/equity/tmus-stock-slips-as-300-b-deutsche-telekom-merger-talks-reportedly-hit-a-roadblock/cZN4lirRJP6">TMUS Stock Slips As $300B Deutsche Telekom Merger Talks Reportedly Hit A Roadblock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAge Labs logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with rel

BioAge Labs Inc.

Novo Nordisk A/S

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.76
Prev Close	$10.87
Open	$10.85
Dividend Yield	0.00%
50-Day Moving Average	$12.08
Beta	1.42
Avg. Volume	1.12M
PE Ratio	-5.65

52-Week High	$25.77
52-Week Low	$9.68
Market Capitalization	$917.97M
EPS (Annual)	-$0.465
Price to Book	1.88
Revenue Per Employee	$824,480.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLUE Fundamentals